MedTrace Logo

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

NCT06505369 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-07-17

No results posted yet for this study

Summary

This is Phase 2, open-label, multicentre, non-randomised study evaluating participants with newly diagnosed MM eligible for high-dose therapy. The goal of the study is to determine if consolidation with T-cell redirectors - Talquetamab and Teclistamab in sequence will improve the response depth: increase MRD negative CR rate.

Conditions

Interventions

DRUG

Daratumumab

Daratumumab will be administered by SC injection

DRUG

Bortezomib

Bortezomib will be administered by SC injection

DRUG

Lenalidomide

Lenalidomide will be administered by oral route

DRUG

Dexamethasone

Dexamethasone will be administered by oral route

DRUG

Talquetamab

Talquetamab will be administered by SC injection

DRUG

Teclistamab

Teclistamab will be administered by SC injection

Sponsors & Collaborators

  • Janssen Pharmaceutica

    collaborator INDUSTRY

  • North Estonia Medical Centre

    lead OTHER

Principal Investigators

  • Diana Loigom, MD · North Estonia Medical Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-19
Primary Completion
2026-11-30
Completion
2028-10-31

Countries

  • Denmark
  • Estonia
  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06505369 on ClinicalTrials.gov